<DOC>
	<DOC>NCT00128544</DOC>
	<brief_summary>This study is being conducted to compare the effectiveness of the combination of valtorcitabine and telbivudine to telbivudine alone in patients with chronic hepatitis B.</brief_summary>
	<brief_title>Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Clinical history compatible with compensated chronic hepatitis B Other protocoldefined inclusion criteria may apply. Patient is pregnant or breastfeeding Patient is coinfected with hepatitis C virus, hepatitis D virus or HIV Patient has previously received lamivudine, adefovir dipivoxil or an investigational antihepatitis B virus (HBV) nucleoside or nucleotide at anytime. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>